Eli Lilly shares surged 4.4% in premarket trading, climbing to $1,181 and extending Friday's record high. The jump pushed the pharmaceutical giant's stock up more than 30% since its April 30 first-quarter earnings report, reflecting investor confidence in its obesity pipeline.

The rally followed positive Phase 3 trial data for retatrutide, the company's experimental triple-hormone agonist targeting weight management. Participants taking 12 mg doses lost an average of approximately 70 pounds over 80 weeks, with one-third achieving a healthy weight range and two-thirds dropping below obesity thresholds.

These results position Eli Lilly as a formidable competitor in the obesity drug market, where retatrutide could challenge established treatments from rivals. The drug's multi-hormone approach addresses several mechanisms involved in weight regulation, potentially offering superior efficacy compared to single-target therapies currently available.

The strong market response suggests investors view this as more than just another obesity drug contender. With shares hitting fresh highs and the company's market capitalization growing substantially, Eli Lilly appears poised to capitalize on the multi-billion-dollar obesity treatment opportunity that has reshaped pharmaceutical investing.